Hepatitis C

Top Story

AbbVie receives CHMP positive opinion for Maviret for chronic HCV

June 23, 2017

AbbVie has received a positive opinion from the Committee for Medicinal Products for Human Use for its ribavirin-free regimen Maviret for the treatment of chronic hepatitis C of all genotypes, according to a press release.

“Maviret represents a new generation of HCV therapy and has the potential to be a shorter, 8-week option for patients living with this serious, chronic illness,” Michael Severino, MD, executive vice president, research and development and chief scientific officer at AbbVie, said in the release. “Today’s CHMP positive opinion takes us closer to delivering on AbbVie’s mission to address continued unmet needs by bringing a new pan-genotypic option to people living with HCV in Europe.”

Gilead Sciences receives CHMP positive opinion for DAA Vosevi

June 23, 2017
Gilead Sciences announced that the Committee for Medicinal Products for Human Use has adopted a positive opinion on the company’s Marketing Authorization…
In the Journals

Interferon-based SVR in HCV reduced risk for extrahepatic manifestations

June 23, 2017
Sustained virologic response following interferon-based antiviral therapy in patients with hepatitis C reduced the risk for extrahepatic manifestations, according to…
Perspective

Multidisciplinary HCV treatment program yields results

Infectious Disease News, June 2017
A hepatitis C virus treatment program at an urban safety-net hospital that used a multidisciplinary team led to nearly one out of every four referrals receiving…
CME CE CNE CPE CPE

HIV/AIDS 1 Hour Update For Florida Health Professionals

No commercial support for this activity.

This is a 1 hour activity designed for home study by healthcare clinicians. Specifically, it meets the 1 hour HIV/AIDS…
More »
In the Journals

SOF/VEL/VOX with, without RBV effective in DAA-experienced HCV patients

June 12, 2017
Fixed dose treatment with sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin for 12 weeks was effective and…
More »
Featured
ASM Microbe

ASM Microbe

Video
Meeting News

VIDEO: Cost to treat HCV could be as low as $80 in the US

November 18, 2016
More »

AbbVie receives CHMP positive opinion for Maviret for chronic HCV

June 23, 2017
AbbVie has received a positive opinion from the Committee for Medicinal Products for Human Use for its ribavirin-free regimen Maviret for the…

Gilead Sciences receives CHMP positive opinion for DAA Vosevi

June 23, 2017
Gilead Sciences announced that the Committee for Medicinal Products for Human Use has adopted a positive opinion on the company’s Marketing…

In the Journals

Interferon-based SVR in HCV reduced risk for extrahepatic manifestations

June 23, 2017
Sustained virologic response following interferon-based antiviral therapy in patients with hepatitis C reduced the risk for extrahepatic…

Perspective

Multidisciplinary HCV treatment program yields results

Infectious Disease News, June 2017
A hepatitis C virus treatment program at an urban safety-net hospital that used a multidisciplinary team led to nearly one out of every four…

Cover Story

CDC’s EIS program molds clinicians into public health professionals

Infectious Disease News, June 2017
The man in the hospital in Puerto Rico had been bitten by a mongoose as he reached inside his backyard chicken coop to retrieve some eggs. The…

At Issue

What are the downstream effects of smaller EIS class sizes?

Infectious Disease News, June 2017
Due to budget concerns, the incoming class of the CDC’s Epidemic Intelligence Service, or EIS, has been reduced to 71 members — 10 fewer…

In the Journals

MELD score determines DAAs’ cost-effectiveness pre- or post-transplant

June 20, 2017
Direct-acting antiviral treatment in patients with hepatitis C and cirrhosis was most cost-effective and cost-saving pre-liver transplant among those…

In the Journals Plus

Electronic HCV screening intervention improves testing, linkage to care in baby boomers

June 16, 2017
An electronic health record clinical decision support tool significantly increased hepatitis C virus screening, as well as follow-up testing and

Experts release new recommendations for the elimination of HCV in the U.S.

June 16, 2017
A recent report from the O’Neill Institute for National and Global Health Law at Georgetown University provides key recommendations for the…

In the Journals

Urban clinic achieves high SVR rates in HCV/HIV coinfected patients

June 14, 2017
Patients with hepatitis C and HIV coinfection had high rates of sustained virologic response in an urban clinical setting with the use of standard…

More Headlines »
Advertisement
Advertisement